The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin showed a reduction in CV outcomes, including CV mortality and heart failure admissions, in patients with T2DM (4). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.